Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nabiximols - GW Pharmaceuticals

Drug Profile

Nabiximols - GW Pharmaceuticals

Alternative Names: Cannabidiol/tetrahydrocannabinol; CBD/THC; CBD:THC; Delta-9-tetrahydrocannabinol/cannabidiol; Delta-9-THC/cannabidiol; Dronabinol/cannabidiol; GW 1000; GW-1000-02; Medicinal cannabis - GW Pharmaceuticals; Nabidiolex®/Tetranabinex®; Sativex; Tetrahydrocannabinol/cannabidiol; THC/CBD; THC:CBD

Latest Information Update: 23 Nov 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GW Pharmaceuticals
  • Developer Almirall S.A.; GW Pharmaceuticals; Neopharm Ltd; Novartis; Otsuka Pharmaceutical
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antidementias; Antiemetics; Antiepileptic drugs; Antihyperglycaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Appetite stimulants; Cannabinoids; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Obesity therapies; Phytotherapies; Skin disorder therapies
  • Mechanism of Action Antioxidants; Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Muscle spasticity; Neuropathic pain
  • Phase I/II Glioblastoma
  • Phase I Post-traumatic stress disorders
  • No development reported Bladder dysfunction; Stomatitis

Most Recent Events

  • 13 Nov 2020 Efficacy data from three phase III trials in multiple sclerosis-related spasticity released by GW Pharmaceuticals
  • 03 Nov 2020 Phase-III clinical trials in Muscle spasticity in USA (Buccal)
  • 10 Sep 2020 GW Pharmaceuticals plans a pivotal Phase III trials in Muscle spasticity (associated with multiple sclerosis) in USA (Buccal) in second half of 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top